A review of 12 antiemetic regimens identified 3 that may be more effective than conventional regimens, a study presented at SABCS 2017 has shown.
A small study of 50 patients undergoing FOLFOX for CRC determined if adding aprepitant to standard antiemetic prophylactic treatment would improve CINV in this patient population.
A post-hoc analysis of 2 clinical trials was conducted to determine the safety and effectiveness of NEPA for managing CINV in patients with lung cancer who received platinum-based chemotherapy.
Delayed CINV was improved significantly in patients receiving highly emetogenic chemotherapy for cancer when thalidomide was added to palonosetron and dexamethasone regimen.
In a poster presentation at SABCS 2016, researchers reported on the efficacy and safety of netupitant/palonosetron (NEPA) for the prevention of CINV in patients receiving highly or moderately emetogenic chemotherapy.
Sign Up for Free e-newsletters
- Study Finds Association Between Folate Intake and Risk of Cutaneous Melanoma
- Melanoma Outcomes Improved With Nivolumab Alone or Plus Ipilimumab
- Oral Contraceptive Use May Not Be Associated With Increased Melanoma Risk
- The Caregivers' Cancer Journey
- Staff Education Leads to Increase in Oncology Rehabilitation Referrals
- Implementing an Ambulatory Adherence Program May Improve Oral Anticancer Medications Compliance
- Exercise Habits Influence Mortality in Adult Survivors of Childhood Cancer
- Managing Dyspnea With Fentanyl in Patients With Cancer at End of Life
- CALM: A Depression Intervention for Cancer Patients at the End of Life
- High BMI Among Premenopausal Women May Improve Risk for Breast Cancer
- Choice of Breast Reconstruction After Mastectomy Affects Satisfaction, Quality of Life
- Gender Bias in Medicine Has Far-Reaching Consequences
- Carfilzomib Benefits May Outweigh Cardiovascular Risk in Multiple Myeloma
- Patient Interest in Melanoma Genetic Risk Testing is Fairly High
- Genetic Link Between Depression and Breast Cancer Remains Unclear
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|